Prefer to read in print? Subscribe for free here
If you would like to feature in the next issue of Pf Magazine, contact us here
January’s articles:
Pf Magazine January 2019 – The state of affairs 2019
Latest articles
Sanofi and GSK COVID-19 vaccine candidate demonstrates positive Phase II results
The Sanofi and GlaxoSmithKline (GSK) COVID-19 vaccine candidate has achieved positive results in all adult age groups in a Phase II study with 722...
First Alzheimer’s disease drug candidate designed by AI enters Phase I clinical trials
The world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) is entering Phase I clinical trials, thanks to a successful collaboration...
Expand and evolve – when specialist services meet
Specialist recruitment and outsourcing consultancy, Evolve, is pleased to announce the integration of Prentice Associates Ltd. The two specialist organisations have both provided recruitment...
Popular articles
New Normal, New Thinking: Life Post COVID-19
New thinking will be required to adapt to the new normal life post COVID-19. I hate to start this article on a negative note, but...
Challenges in recruiting during the pandemic
Richard Clegg, Director of Expion Search and Selection, looks at how COVID-19 has presented many challenges to industry, not least in recruitment and retention...
First Alzheimer’s disease drug candidate designed by AI enters Phase I clinical trials
The world’s first Alzheimer’s disease (AD) drug candidate designed by artificial intelligence (AI) is entering Phase I clinical trials, thanks to a successful collaboration...
Study shows anti-parasitic drug ivermectin kills coronavirus within 48 hours
A collaborative study led by the Monash Biomedicine Discovery Institute (BDI) with the Peter Doherty Institute of Infection and Immunity (Doherty Institute), a joint...
Sanofi and GSK COVID-19 vaccine candidate demonstrates positive Phase II results
The Sanofi and GlaxoSmithKline (GSK) COVID-19 vaccine candidate has achieved positive results in all adult age groups in a Phase II study with 722...